Primer and kit for detecting FOXP1:: ABL1 fusion gene as well as use method and application

By designing specific primers and kits, combined with PCR technology, quantitative detection of FOXP1::ABL1 fusion gene is achieved, solving the problem of the lack of accurate detection of FOXP1::ABL1 gene in the prior art, and providing an emergency lymphocytic leukemia Key evidence for diagnostic and therapeutic monitoring, improving the accuracy and sensitivity of the detection.

CN119082305APending Publication Date: 2024-12-06FIRST AFFILIATED HOSPITAL OF DALIAN MEDICAL UNIV +1
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411351149.4
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2024-09-26
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

There is a lack of accurate detection methods for FOXP1::ABL1 fusion gene in the prior art, making it difficult to effectively diagnose acute lymphocytic leukemia, especially tiny residual lesions and treatment monitoring in patients with positive FOXP1::ABL1 gene fusion.

Method used

A specific FOXP1::ABL1 primer and ABL1 internal reference primer probe sequence were designed, combined with PCR technology and fluorescent labeling, and a kit for FOXP1::ABL1 fusion gene was developed to achieve the reverse transcription of cDNA and nucleic acid amplification reagents. Quantitative detection of FOXP1::ABL1 fusion gene.

Benefits of technology

Provides molecular biological evidence for the diagnosis of acute lymphocytic leukemia, improves the accuracy and sensitivity of diagnosis and treatment, can detect low-concentration samples, is suitable for bone marrow or peripheral blood samples, and has many advantages of good specificity and high reproducibility. , suitable for treatment monitoring and prognosis evaluation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0005062394120000091
    Figure BDA0005062394120000091
  • Figure BDA0005062394120000111
    Figure BDA0005062394120000111
  • Figure BDA0005062394120000112
    Figure BDA0005062394120000112
Patent Text Reader

Abstract

The invention relates to the technical field of gene detection (IPC classification number: C12Q), in particular to a primer for detecting FOXP1:: ABL1 fusion gene and a kit thereof. The primer comprises an FOXP1:: ABL1 primer probe sequence and an ABL1 internal reference primer probe sequence. The kit comprises a nucleic acid amplification reagent, a reverse transcription reagent, a reference substance and a reference substance. Through effective detection of fusion of the rare FOXP1:: ABL1 gene, key molecular biology evidence can be provided for diagnosis of acute lymphoblastic leukemia. Meanwhile, FOXP1:: ABL1 gene fusion quantitative detection is carried out on FOXP1:: ABL1 gene fusion positive patients, so that the FOXP1:: ABL1 gene fusion quantitative detection can be used for detecting leukemia minimal residual lesions, and the FOXP1:: ABL1 gene fusion quantitative detection method has important significance on treatment monitoring and formulation of a treatment scheme and can provide help for clinical treatment and prognosis evaluation.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of gene detection (IPC classification number: C12Q), and in particular to a primer for detecting FOXP1::ABL1 fusion gene and a kit thereof. Background Art

[0002] Acute lymphoblastic leukemia (ALL), as a type of acute leukemia, is one of the most common acute leukemias in adults, accounting for about 20% to 30% of acute leukemias in adults; at the same time, acute lymphoblastic leukemia is also the most common malignant tumor in children, accounting for 80% of acute leukemias in children. Leukemia fusion genes can be used as molecular biological specific markers for diagnosing different types of leukemia and an important basis for determining the diagnosis.

[0003] The FOXP1 (Forkhead box protein P1) gene is located on the short arm of chromosome 3, region 1, band 3, and the ABL1 (non-receptor tyrosine kinase) gene is located on the long arm of chromosome 9, region 3, band 4. It has been reported in the literature that some patients with acute lymphoblastic leukemia have FOXP1::ABL1 gene fusion, resulting in the fusion expression of FOXP1 exon 9 and ABL1 exon 4 at the mRNA level. At present, most of the detection of ABL fusion genes is for the detection of BCR-ABL fusion genes. For example, Chinese patent CN112301129A discloses a R-ABL fusion gene detection kit and a BCR-ABL fusion gene detection method; Chinese patent CN104328213B discloses a primer and a kit for a rapid detection method of BCR-ABL fusion genes. At the same time, some technologies have explored the detection methods of ALL-related fusion genes. For example, Chinese patent CN112143812A proposes a primer and probe, composition and method for screening and identifying Ph-like ALL-related fusion genes using fluorescent PCR technology; Chinese patent CN112410426B discloses a primer and probe, composition and method for screening and identifying PAX5 rearrangement-related fusion genes using fluorescent PCR technology. However, there is no technical concept in the prior art that focuses on the precise detection of FOXP1::ABL1 gene fusion. Summary of the invention

[0004] The present invention provides a primer, a kit and a method for using a FOXP1::ABL1 fusion gene, which can provide key molecular biological evidence for the diagnosis of acute lymphoblastic leukemia by effectively detecting the rare FOXP1::ABL1 gene fusion. At the same time, quantitative detection of FOXP1::ABL1 gene fusion in patients with positive FOXP1::ABL1 gene fusion can be used to detect tiny residual lesions of leukemia, which is of great significance for treatment monitoring and formulation of treatment plans, and can provide help for clinical treatment and prognosis evaluation.

[0005] The first aspect of the present invention provides a primer for detecting the FOXP1::ABL1 fusion gene, wherein the primer comprises a FOXP1::ABL1 primer probe sequence and an ABL1 internal reference primer probe sequence.

[0006] Preferably, the FOXP1::ABL1 primer probe sequence comprises:

[0007] FOXP1::ABL1-F:5'-TCAGTGGTAACCCTTCCCTTA-3'

[0008] FOXP1::ABL1-R:5'-GGATAATGGAGCGTGGTGAT-3'

[0009] FOXP1::ABL1-P:

[0010] 5'-FAM-GCTTTACAGCTCTACGTCTCCTCCGAGA-BHQ1-3'.

[0011] Preferably, the ABL1 internal reference primer probe sequence includes:

[0012] ABL1 internal reference-F: 5'-AATTGCTACCTATGGCATGT-3'

[0013] ABL1 internal reference-R: 5'-CTTTTCCACTTCGTCTGAGA-3'

[0014] ABL1 internal control-P: 5'-FAM-GACCTGTCCCAGGTGTATGAGCT-BHQ1-3'.

[0015] The present invention effectively detects the rare FOXP1::ABL1 gene fusion through specific primer design, and can provide key molecular biological evidence for the diagnosis of acute lymphoblastic leukemia. After exploration, it was unexpectedly found that when the FOXP1::ABL1 primer probe sequence and the ABL1 internal reference primer probe sequence are composed of the above-mentioned exon DNA chain, the FOXP1::ABL1 fusion gene and the ABL1 internal reference gene can be accurately captured and identified; it provides a new idea for the efficient and accurate detection of the FOXP1::ABL1 fusion gene, thereby optimizing the diagnosis and treatment of acute lymphoblastic leukemia.

[0016] The second aspect of the present invention provides a kit for detecting FOXP1::ABL1 fusion gene; the kit comprises: a nucleic acid amplification reagent, a reverse transcription reagent, a control substance and a reference substance.

[0017] The nucleic acid amplification reagents include FOXP1::ABL1 PCR reaction solution, ABL1 internal reference gene PCR reaction solution and PCRMIX.

[0018] The FOXP1::ABL1 PCR reaction solution is the above-mentioned FOXP1::ABL1 primer probe sequence.

[0019] The ABL1 internal reference gene PCR reaction solution is the above-mentioned ABL1 internal reference primer probe sequence.

[0020] Preferably, the reverse transcription reagent consists of MIX 1 and MIX 2; the volume ratio of MIX 1 to MIX 2 is (2-5):(1-3), preferably 3:2.

[0021] There is no specific limitation on the fluorescent labeling group of the primer probe, and any fluorescent group commonly used in the art can be selected, for example, any one of FAM, VIC, HEX, TexasRed, CY5, TET, JOE, CY3, TAMRA, ROX, LCRED640, and LCRED705.

[0022] In some preferred embodiments, different fluorescent groups may be used in the FOXP1::ABL1 PCR reaction solution and the ABL1 internal reference gene PCR reaction solution, so that the two reaction solutions are combined into one tube for detection.

[0023] Note: Storage conditions of this kit: Store away from light at -20℃±4℃. Transportation conditions: Transport in a sealed foam box with ice packs. The transportation time shall not exceed 4 days and the temperature shall not be higher than room temperature. After arriving at the destination, it shall be frozen according to the storage conditions. Validity period: 12 months.

[0024] Also, this kit should be kept away from repeated freezing and thawing. Please mix the reagents thoroughly before use after thawing.

[0025] The third aspect of the present invention provides a method for using the above-mentioned kit, which specifically comprises:

[0026] S1. Sample processing: extract RNA from the sample to be tested, and mix the extracted RNA with RNase-Free water to dissolve it to obtain a reverse transcription template for later use;

[0027] S2. Reverse transcription of cDNA;

[0028] S3. Prepare amplification reagents and add samples;

[0029] S4. PCR amplification reaction;

[0030] S5. Data collection and analysis.

[0031] The S1 step can extract the RNA in the sample to be tested using the extraction method commonly used in the art. It is recommended to use commercial reagents or kits to extract RNA (such as Invitrogen Trizol reagent). It is recommended to test the extracted RNA immediately, otherwise please store it below -80°C. During the test, mix the extracted RNA with RNase-Free water to dissolve it, and take 10μL of the mixture as the reverse transcription template; at the same time, prepare a negative control sample, which is specifically the same volume of RNase-Free water.

[0032] In order to improve the specificity of the kit for detecting the FOXP1::ABL1 fusion gene, preferably, the step S2 is specifically to place the reverse transcription template obtained in step S1 and the reverse transcription reagent in a PCR amplifier for reverse transcription to synthesize cDNA; the reverse transcription conditions are: react at 37° C. for 1 hour, then react at 70° C. for 10 minutes to obtain a cDNA template.

[0033] Preferably, the S3 step specifically includes:

[0034] 3.1 Prepare nucleic acid amplification reagents: Mix FOXP1::ABL1 PCR reaction solution, ABL1 internal reference gene PCR reaction solution and PCR MIX, melt at room temperature and shake to mix, centrifuge at 1000-3000 rpm for 5-30 seconds to obtain nucleic acid amplification reagents; more preferably, centrifuge at 2000 rpm for 10 seconds;

[0035] 3.2 Configure the reaction system: Take each cDNA template to detect the FOXP1::ABL1 fusion gene and the ABL1 internal reference gene, so configure reaction system 1 and reaction system 2 respectively:

[0036] Preferably, the reaction system 1 is specifically as follows: for the FOXP1::ABL1 fusion gene, the FOXP1::ABL1 PCR reaction solution, PCR MIX and cDNA template are mixed; the volume ratio of the three is (5-10): (10-20): (1-8); preferably, the volume ratio of the three is 7:13:5.

[0037] Preferably, the reaction system 2 is specifically as follows: for the ABL1 internal reference gene, the ABL1 internal reference gene PCR reaction solution, PCRMIX and cDNA template are mixed; the volume ratio of the three is (5-10): (10-20): (1-8); preferably, the volume ratio of the three is 7:13:5.

[0038] 3.3 Transfer the configured reaction system 1 and reaction system 2 to the PCR amplification instrument for detection.

[0039] In order to further improve the accuracy and sensitivity of the kit for detecting the FOXP1::ABL1 fusion gene, preferably, the specific conditions for PCR amplification in step S4 are: ① Pre-reaction stage: 42°C, 5 min; 94°C, 3 min; ② PCR cycle stage: 94°C, 15 s; 60°C, 60 s; after 30-50 cycles; more preferably 40 cycles. After the cycle is completed, the fluorescence model is collected.

[0040] Note: When using a PCR amplification instrument for testing, the detection channel is set to: FAM, and the reference fluorescence is set to none.

[0041] The data collection in step S5 is achieved by the supporting software of the PCR amplification instrument.

[0042] The present invention can obtain accurate detection results by optimizing the use of the kit and adopting simple and easy detection steps; in particular, through specific reverse transcription cDNA reaction conditions and specific nucleic acid amplification reagent preparation, the specificity, reproducibility and sensitivity of the detection method are improved at the same time. After multi-dimensional method and sample verification, the detection kit of the present invention has multiple advantages of good specificity for FOXP1::ABL1 fusion gene, high reproducibility of test results, and accurate test results. The detection limit of the kit of the present invention is low, and the minimum detection limit for the ABL1 internal reference gene is 1000 copies, and the minimum detection limit for the FOXP1::ABL1 fusion gene is 15 copies; it can achieve effective identification of low-concentration samples and has a wider range of applications.

[0043] Keep the following points in mind when collecting and analyzing data:

[0044] (1) Determination of baseline: The software defaults to setting the average fluorescence signal of 3-15 cycles as the baseline. In the experiment, the section with the smallest fluctuation and the most stable curve is generally selected as the baseline. The user can adjust it at his / her discretion according to the actual situation. The starting point of the baseline should avoid the initial few cycles. This is because the high temperature in this stage will cause the signal to increase. The signal should be selected where it has dropped to the background height and can remain stable. The end point of the baseline should avoid covering the place where the signal has begun to increase significantly. Depending on the trend of the experimental curve, the stop value can generally be selected 2-3 Ct values ​​before the first obvious inflection point of the entire amplification curve; the start value should be selected with the principle that the starting point and the end point should be separated by more than 8 cycles to better meet the mathematical requirements of the statistical baseline standard deviation.

[0045] (2) Determination of the threshold value: In the case of no amplification in the negative control, the threshold value is set at the highest point of the no amplification curve of the negative control sample, that is, the highest point of the no amplification growth curve (that is, no dot appears in the "Component" column of the result analysis), and the negative control is not detected as a principle to determine the starting threshold value.

[0046] Note: This kit is suitable for testing bone marrow or peripheral blood samples. Use EDTA anticoagulant tubes to collect samples.

[0047] The PCR amplifier used in the PCR test using the kit is not specifically limited, and any PCR amplifier commonly used in the art may be used; for example, a PCR fluorescence detector such as the Bio-Rad CFX96 fluorescence PCR detector.

[0048] The fourth aspect of the present invention provides the use of the above-mentioned kit and the method of using the same in the detection of FOXP1::ABL1 fusion gene of acute lymphoblastic leukemia in the peripheral blood or bone marrow of an organism.

[0049] Beneficial effects:

[0050] The present invention provides a primer, a kit and a method for using a FOXP1::ABL1 fusion gene, which has the following advantages:

[0051] (1) Through specific primer design, the rare FOXP1::ABL1 gene fusion can be effectively detected, providing key molecular biological evidence for the diagnosis of acute lymphoblastic leukemia.

[0052] (2) A kit consisting of a reverse transcription reagent, a nucleic acid amplification reagent, a control substance and a reference substance is used, and PCR is combined with real-time fluorescent probe technology to achieve a quantitative detection method for the RNA content of the FOXP1::ABL1 fusion gene in the sample to be tested; the method has strong practicality in actual operation.

[0053] (3) By optimizing the method of using the kit and adopting simple and easy detection steps, accurate detection results can be obtained; after multi-dimensional method and sample verification, the detection kit of the present invention has many advantages such as good specificity for FOXP1::ABL1 fusion gene, high reproducibility of test results, and accurate test results.

[0054] (4) The detection limit of the kit of the present invention is low, with the minimum detection limit for the ABL1 internal reference gene being 1000 copies and the minimum detection limit for the FOXP1::ABL1 fusion gene being 15 copies; it can achieve effective identification of low-concentration samples and has a wider range of applications.

[0055] (5) This technology can be used to quantitatively detect FOXP1::ABL1 gene fusion in patients with positive FOXP1::ABL1 gene fusion, and can be used to detect tiny residual leukemia lesions. It is of great significance for treatment monitoring and formulation of treatment plans, and can provide assistance for clinical treatment and prognosis assessment. BRIEF DESCRIPTION OF THE DRAWINGS

[0056] Figure 1 .PCR amplification curves of ABL1 internal reference gene references 1-4.

[0057] Figure 2 .PCR amplification curves of FOXP1::ABL1 fusion gene references 1-4.

[0058] Figure 3 . Amplification curve of reaction system 2 (ABL1 internal reference gene) during specificity test; the red curve corresponds to the positive control of RNA solution extracted from ABL1 pseudovirus, the green curve corresponds to the negative control, and the blue curve corresponds to the sample to be tested.

[0059] Figure 4 . Amplification curve of reaction system 1 (FOXP1::ABL1) during specificity test; the red curve corresponds to the positive control of RNA solution extracted from FOXP1::ABL1 pseudovirus, the green curve corresponds to the negative control, and the blue curve corresponds to the sample to be tested.

[0060] Figure 5 .PCR amplification curve of the ABL1 internal reference gene in the sample during the repeatability test.

[0061] Figure 6 .PCR amplification curve of FOXP1::ABL1 fusion gene in samples during repeatability test.

[0062] Figure 7 .PCR amplification curve of the ABL1 internal reference gene in positive samples.

[0063] Figure 8.PCR amplification curve of FOXP1::ABL1 fusion gene in positive samples. DETAILED DESCRIPTION

[0064] Unless otherwise specified, the room temperature in the embodiments of the present invention is 25°C.

[0065] Example 1.

[0066] In a first aspect, the present embodiment provides a primer for detecting the FOXP1::ABL1 fusion gene, wherein the primer includes a FOXP1::ABL1 primer probe sequence and an ABL1 internal reference primer probe sequence.

[0067] The FOXP1::ABL1 primer probe sequence includes:

[0068] FOXP1::ABL1-F:5'-TCAGTGGTAACCCTTCCCTTA-3'

[0069] FOXP1::ABL1-R:5'-GGATAATGGAGCGTGGTGAT-3'

[0070] FOXP1::ABL1-P:

[0071] 5'-FAM-GCTTTACAGCTCTACGTCTCCTCCGAGA-BHQ1-3'.

[0072] The ABL1 internal reference primer probe sequence includes:

[0073] ABL1 internal reference-F: 5'-AATTGCTACCTATGGCATGT-3'

[0074] ABL1 internal reference-R: 5'-CTTTTCCACTTCGTCTGAGA-3'

[0075] ABL1 internal control-P: 5'-FAM-GACCTGTCCCAGGTGTATGAGCT-BHQ1-3'.

[0076] In a second aspect, this embodiment provides a kit for detecting the FOXP1::ABL1 fusion gene; the kit comprises: a nucleic acid amplification reagent, a reverse transcription reagent, a control substance and a reference substance.

[0077] The nucleic acid amplification reagents, reverse transcription reagents, control substances and reference substances are all from Shanghai Yuanqi Biotechnology Co., Ltd.

[0078] The nucleic acid amplification reagents include FOXP1::ABL1 PCR reaction solution, ABL1 internal reference gene PCR reaction solution and PCRMIX.

[0079] The FOXP1::ABL1 PCR reaction solution is the above-mentioned FOXP1::ABL1 primer probe sequence.

[0080] The ABL1 internal reference gene PCR reaction solution is the above-mentioned ABL1 internal reference primer probe sequence.

[0081] The reverse transcription reagent consists of MIX 1 and MIX 2; the volume ratio of MIX 1 to MIX 2 is 3:2, with a total of 10 μL.

[0082] The third aspect of this embodiment provides a method for using the above-mentioned kit, which specifically includes:

[0083] S1. Sample processing: extract RNA from the sample to be tested, and mix the extracted RNA with RNase-Free water to dissolve it to obtain a reverse transcription template for later use;

[0084] S2. Reverse transcription of cDNA;

[0085] S3. Prepare amplification reagents and add samples;

[0086] S4. PCR amplification reaction;

[0087] S5. Data collection and analysis.

[0088] The S1 step uses the Trizol method to extract RNA from the sample to be tested. During the test, the extracted RNA precipitate is mixed and dissolved with RNase-Free water (the volume of RNase-Free water is 50 μL), and 10 μL of the mixture is taken as the reverse transcription template; at the same time, a negative control sample is prepared, and the negative control sample is specifically the same volume of RNase-Free water. The selection of the sample to be tested is specifically described in the test method.

[0089] The step S2 specifically includes placing the reverse transcription template obtained in step S1 and the reverse transcription reagent in a PCR amplifier for mixing and reverse transcription to synthesize cDNA; the reverse transcription conditions are: reacting at 37° C. for 1 hour and then reacting at 70° C. for 10 minutes to obtain a cDNA template.

[0090] The S3 step specifically includes:

[0091] 3.1 Prepare nucleic acid amplification reagents: Mix FOXP1::ABL1 PCR reaction solution and ABL1 internal reference gene PCR reaction solution with PCR MIX (volume ratio of 7:13), melt at room temperature and shake to mix, centrifuge at 2000 rpm for 10 seconds to obtain nucleic acid amplification reagents;

[0092] 3.2 Configure the reaction system: Take each cDNA template to detect the FOXP1::ABL1 fusion gene and the ABL1 internal reference gene, so configure reaction system 1 and reaction system 2 respectively:

[0093] Reaction system 1 is specifically as follows: for the FOXP1::ABL1 fusion gene, FOXP1::ABL1 PCR reaction solution, PCRMIX and cDNA template are mixed; the volume ratio of the three is 7:13:5, and the volume of reaction system 1 is 25 μL in total.

[0094] Reaction system 2 is specifically as follows: for the ABL1 internal reference gene, the ABL1 internal reference gene PCR reaction solution, PCR MIX and cDNA template are mixed; the volume ratio of the three is 7:13:5, and the volume of reaction system 2 is 25 μL in total.

[0095] 3.3 Transfer the configured reaction system 1 and reaction system 2 to the PCR amplification instrument for detection.

[0096] The specific conditions of PCR amplification in step S4 are: ① pre-reaction stage: 42°C, 5 min; 94°C, 3 min; ② PCR cycle stage: 94°C, 15 s; 60°C, 60 s; 40 cycles. After 40 cycles, the fluorescence model is collected.

[0097] Note: When using a PCR amplification instrument for testing, the detection channel is set to: FAM, and the reference fluorescence is set to none.

[0098] The data collection in step S5 is achieved by the supporting software of the PCR amplification instrument.

[0099] The PCR amplification instrument used in this kit is the Bio-Rad CFX96 fluorescence PCR instrument.

[0100] Performance Testing Methods

[0101] 1. Determination of method effectiveness:

[0102] The linear standard curves of the FOXP1::ABL1 fusion gene and the ABL1 internal reference gene were used for PCR detection (refer to steps S2 to S5 in the method for using the kit in Example 1), wherein the information of each reference substance is shown in Table 1 below.

[0103] Table 1

[0104] Reference product name Reference concentration FOXP1::ABL1 fusion gene linear standard 1 <![CDATA[1.5×10 6 copies]]> FOXP1::ABL1 fusion gene linear standard 2 <![CDATA[1.5×10 5 copies]]> FOXP1::ABL1 fusion gene linear standard 3 <![CDATA[1.5×10 4 copies]]> FOXP1::ABL1 Fusion Gene Linear Standard 4 <![CDATA[1.5×10 3 copies]]> ABL1 internal reference gene linear standard 1 <![CDATA[1×10 6 copies]]> ABL1 internal reference gene linear standard 2 <![CDATA[1×10 5 copies]]> ABL1 internal reference gene linear standard 3 <![CDATA[1×10 4 copies]]> ABL1 internal reference gene linear standard 4 <![CDATA[1×10 3 copies]]>

[0105] C of linear standards 1-4 of FOXP1::ABL1 fusion gene and ABL1 internal reference gene T The values ​​should be ≤36, and the absolute value of the standard curve fit should be ≥0.980.T The value should be ≥38 or display "Undet". The test results of the final reference and negative control meet the above requirements.

[0106] 2. Qualitative determination method: According to the reaction solution C T The basis for qualitative judgment of the value is shown in Table 1 below.

[0107] Table 1

[0108]

[0109] a: After retesting, if the C T If the C value of FOXP1::ABL1 PCR reaction solution is less than 38, the FOXP1::ABL1 fusion gene is positive. T Value ≥38, FOXP1::ABL1 fusion gene RNA is below the minimum detection limit.

[0110] b: For internal reference reaction solution C T The C value is >36 and the C value of FOXP1::ABL1 PCR reaction solution T For samples with a value > 36, it is necessary to increase the sample volume, re-extract RNA and perform PCR detection (i.e., repeat steps S1 to S5 after increasing the sample volume), and refer to Table 1 for the test results. T Value>36 and FOXP1::ABL1 reaction solution C T If the value is >36, the sample is judged to not meet the requirements.

[0111] 3. Quantitative determination method:

[0112] 1) Drawing a standard curve: Linear standards 1-4 of the FOXP1::ABL1 fusion gene and the ABL1 internal reference gene were used for PCR detection (refer to steps S2 to S5 in the method for using the kit in Example 1). Specifically, the linear standards 1-4 were added to the two reaction systems in step S3 in the amounts shown in Table 1 for measurement.

[0113] The amount of FOXP1::ABL1 fusion gene linear standards 1-4 added to reaction system 1 (FOXP1::ABL1 fusion gene) was set to: 1.5×10 6 , 1.5×10 5 , 1.5×10 4 , 1.5×10 3 The amount of ABL1 internal reference gene linear standard 1-4 added to reaction system 2 (ABL1 internal reference gene) was set to: 1×10 6 , 1×10 5 , 1×104 , 1×10 3 After the PCR amplification reaction is completed, a standard curve can be drawn according to the added amount of linear standards 1-4 and the fluorescence signal test results.

[0114] 2) Substitute the test results of the samples into the two standard curves in step 1) to obtain the detection concentration of the FOXP1::ABL1 fusion gene (A) and the detection concentration of the ABL1 internal reference gene (B) of each sample.

[0115] 3) Analysis of test results:

[0116] 3.1 If the sample: FOXP1::ABL1 fusion gene detection concentration (A)> 1×10 7 copies, that is, they are not within the linear range and need to be appropriately diluted and retested.

[0117] 3.2 If the sample: ABL1 internal reference gene detection concentration (B)> 1×10 7 copies, that is, they are not within the linear range and need to be appropriately diluted and retested.

[0118] 3.3 If the sample: the test result is 5×10 1 copies≤FOXP1::ABL1 fusion gene detection concentration (A)≤1×10 7 copies, and 1×10 3 copies≤ABL1 internal reference gene detection concentration (B)≤1×10 7 If there are 100 copies, the output fusion gene ratio is the ratio of the FOXP1::ABL1 fusion gene detection concentration (A) to the ABL1 internal reference gene detection concentration (B) (i.e. A / B) × 100%.

[0119] Among them, the PCR amplification curves of ABL1 internal reference gene linear standards 1-4 are shown in Figure 1 ; The corresponding standard curve parameters are: E = 104.8%, R 2 =0.999%, Slope=-3.213, y-int=42.372.

[0120] The PCR amplification curves of FOXP1::ABL1 fusion gene linear standards 1-4 are shown in Figure 2 ; The corresponding standard curve parameters are: E = 99.7%, R 2 =0.999%, Slope=-3.328, y-int=41.247.

[0121] 4. Specificity test verification

[0122] Take 20 FOXP1::ABL1 negative samples (source: Ruiang Gene), and perform PCR detection with reference to steps S1-S5 of the kit usage method in Example 1 to verify the specificity of this kit; the test results are shown in Figure 3 and Figure 4 .

[0123] The test results of each sample under the conditions of reaction solution 2 (ABL1 internal reference gene) are shown in Table 2 below. (N / A: No signal detected)

[0124] Table 2

[0125]

[0126]

[0127] The test results of each sample under the reaction solution 1 (FOXP1::ABL1 fusion gene) condition are shown in Table 3 below. (N / A: No signal detected) Table 3

[0128]

[0129]

[0130] Combining the test results in Table 2 and Table 3, it can be seen that the ABL1 internal reference gene test results of the 31 samples were normal, and the FOXP1::ABL1 fusion gene results were all no signal detected. The above results show that the specificity of this kit is good.

[0131] 5. Determination of Detection Limit

[0132] By performing PCR detection on the detection limit reference (plasmid dilutions of different concentrations) (refer to steps S3 to S5 in the method of using the kit in Example 1), the detection limit of the kit of the present invention for the FOXP1::ABL1 fusion gene and the ABL1 internal reference gene was determined. The test results are shown in the table below. According to the test results in Table 4, the minimum detection limit of the ABL1 internal reference gene of the kit is 1000 copies, and the minimum detection limit of the FOXP1::ABL1 fusion gene of the kit is 15 copies.

[0133] Note: The negative control in Table 4 is high-purity water.

[0134] Table 4

[0135]

[0136]

[0137] 6. Repeatability:

[0138] The reproducibility of the detection results of ABL1 internal reference gene and FOXP1::ABL1 fusion gene was investigated respectively.

[0139] ABL1 internal reference gene: The same sample (specifically, the sample is RNA extracted from pseudovirus) was tested 10 times (corresponding to reaction system 2). The PCR test curve is shown in Figure 5 The 10 test results are recorded in Table 5, and the CV value of the 10 test results is calculated to be 0.47%, indicating that the detection kit has good repeatability for the ABL1 internal reference gene determination results.

[0140] FOXP1::ABL1 fusion gene: The same sample (specifically, RNA extracted from pseudovirus) was tested 10 times (corresponding to reaction system 1). The PCR test curve is shown in Figure 6 The 10 test results are recorded in Table 5, and the CV value of the 10 test results is calculated to be 0.94%, indicating that the detection results of the detection kit for the FOXP1::ABL1 fusion gene have good repeatability.

[0141] Table 5

[0142] Sample name Detection of genes <![CDATA[C T Value]]> Sample name Detection of genes <![CDATA[C T Value]]> Repeat 1 ABL1 33.27 Repeat 1 FOXP1::ABL1 32.63 Repeat 2 ABL1 33.26 Repeat 2 FOXP1::ABL1 32.54 Repeat 3 ABL1 32.74 Repeat 3 FOXP1::ABL1 33.11 Repeat 4 ABL1 33.12 Repeat 4 FOXP1::ABL1 32.24 Repeat 5 ABL1 33.06 Repeat 5 FOXP1::ABL1 33 Repeat 6 ABL1 33.09 Repeat 6 FOXP1::ABL1 32.7 Repeat 7 ABL1 33.15 Repeat 7 FOXP1::ABL1 33.12 Repeat 8 ABL1 33.16 Repeat 8 FOXP1::ABL1 32.96 Repeat 9 ABL1 32.96 Repeat 9 FOXP1::ABL1 33.06 Repeat 10 ABL1 33.15 Repeat 10 FOXP1::ABL1 33.16

[0143] 7. Sample test

[0144] According to the method of using the kit in Example 1, 10 positive samples from the Department of Hematology of the First Affiliated Hospital of Dalian Medical University (sample 8 was a bone marrow sample and the remaining 9 samples were peripheral blood samples) were tested, and the fusion gene ratio was calculated according to the ratio of the FOXP1::ABL1 fusion gene detection concentration to the ABL1 internal reference gene detection concentration; the PCR amplification curve of the positive sample is shown in Figure 7 , Figure 8 , the test results of each positive sample are shown in Table 6 below.

[0145] Table 6

[0146]

Claims

1. A primer for detecting FOXP1::ABL1 fusion gene, characterized in that: The primers include a FOXP1::ABL1 primer probe sequence and an ABL1 internal reference primer probe sequence.

2. The primer for detecting FOXP1::ABL1 fusion gene according to claim 1, characterized in that: The FOXP1::ABL1 primer probe sequence includes: FOXP1::ABL1-F:5'-TCAGTGGTAACCCTTCCCTTA-3' FOXP1::ABL1-R:5'-GGATAATGGAGCGTGGTGAT-3' FOXP1::ABL1-P:5'-FAM-GCTTTACAGCTCTACGTCTCCTCCGAGA-BHQ1-3'.

3. The primer for detecting FOXP1::ABL1 fusion gene according to claim 1 or 2, characterized in that: The ABL1 internal reference primer probe sequence includes: ABL1 internal reference-F: 5'-AATTGCTACCTATGGCATGT-3' ABL1 internal reference-R: 5'-CTTTTCCACTTCGTCTGAGA-3' ABL1 internal control-P: 5'-FAM-GACCTGTCCCAGGTGTATGAGCT-BHQ1-3'.

4. A kit for detecting FOXP1::ABL1 fusion gene, characterized in that: The kit comprises: a nucleic acid amplification reagent, a reverse transcription reagent, a control substance and a reference substance; The nucleic acid amplification reagent includes FOXP1::ABL1 PCR reaction solution, ABL1 internal reference gene PCR reaction solution and PCR MIX; The FOXP1::ABL1 PCR reaction solution is the FOXP1::ABL1 primer probe sequence according to claim 2. The ABL1 internal reference gene PCR reaction solution is the ABL1 internal reference primer probe sequence described in claim 3.

5. A method for using the kit according to claim 4, characterized in that: The method for using the kit specifically includes: S1. Sample processing: extract RNA from the sample to be tested, and mix the extracted RNA with RNase-Free water to dissolve it to obtain a reverse transcription template for later use; S2. Reverse transcription of cDNA; S3. Prepare amplification reagents and add samples; S4. PCR amplification reaction; S5. Data collection and analysis.

6. The method for using the kit according to claim 5, characterized in that: The S3 step specifically includes: 3.1 Prepare nucleic acid amplification reagents: Mix FOXP1::ABL1 PCR reaction solution, ABL1 internal reference gene PCR reaction solution and PCRMIX, melt at room temperature and shake to mix, centrifuge at 1000-3000 rpm for 5-30 seconds to obtain nucleic acid amplification reagents; 3.2 Configure the reaction system: Take each cDNA template to detect the FOXP1::ABL1 fusion gene and the ABL1 internal reference gene, so configure reaction system 1 and reaction system 2 respectively: 3.3 Transfer the configured reaction system 1 and reaction system 2 to the PCR amplification instrument for detection.

7. The method for using the kit according to claim 6, characterized in that: The reaction system 1 is specifically as follows: for the FOXP1::ABL1 fusion gene, the FOXP1::ABL1 PCR reaction solution, PCR MIX and cDNA template are mixed; the volume ratio of the three is (5-10):(10-20):(1-8); preferably, the volume ratio of the three is 7:13:

5.

8. The method for using the kit according to claim 6, characterized in that: The reaction system 2 is specifically as follows: for the ABL1 internal reference gene, the ABL1 internal reference gene PCR reaction solution, PCR MIX and cDNA template are mixed; the volume ratio of the three is (5-10): (10-20): (1-8); preferably, the volume ratio of the three is 7:13:

5.

9. The method for using the kit according to claim 6, characterized in that: The specific conditions of PCR amplification in step S4 are as follows: ① pre-reaction stage: 42°C, 5 min; 94°C, 3 min; ② PCR cycle stage: 94°C, 15 s; 60°C, 60 s; after 30-50 cycles; collecting the fluorescence model after the cycle is completed.

10. A use of the kit according to claim 4 or the method of using the kit according to claims 5 to 9, characterized in that: Applied to the detection of FOXP1::ABL1 fusion gene of acute lymphoblastic leukemia in peripheral blood or bone marrow of organisms.